As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

Pfizer’s stock climbed 2.4% in morning trading, while Merck shares gained 1.7%. As Cantor Fitzgerald analyst Carter Gould put it, Pfizer’s deal with 3SBio thrusts the company into the PD-1 ...

Pfizer on Tuesday announced a cancer drug licensing deal with Chinese biotech 3SBio that includes a $1.25 billion upfront payment and $4.8 billion in potential earnouts.

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely watched immunotherapy ivonescimab.

Pfizer said SSGJ-707 has shown promising efficacy and safety data, and 3Sbio plans to initiate the first Phase 3 study in China sometime this year. Based on this limited data, Cantor's Gould could ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical ...